Search

Background: Caffeine is a widely recognized ergogenic aid for enhancing exercise performance. However, its effect on throwing performance has been less studied, yielding contradictory results., Objectives: The main aim of the study was to analyze the potential ergogenic effects of a moderate dose of caffeine (3 mg·kg -1 body mass) on vertical jump performance and throwing distance during a simulated competition in trained discus and hammer throwers., Methods: In a randomized, counterbalanced, and repeated measures design, 14 well-trained throwers (9 hammer throwers and 5 discus throwers; age 24.8 ± 6.3 years old, training 14.9 ± 5.0 h per week, competing experience 10.5 ± 6.1 years) performed a countermovement jump (CMJ) test, a modified throw, and a complete throw after the ingestion of 3 mg·kg⁻¹ body mass of caffeine or a placebo. Each participant performed three maximal-effort valid modified throws of his/her respective event (i.e., hammer or discus throw), plus three maximal-effort valid official throws (up to five tries, respectively, in case any attempt was called as foul). Throwing distance was measured according to World Athletics regulations using a metal tape, while release speed was assessed with a radar device. After the performance measurements, participants completed a form about side effects prevalence., Results: Caffeine, compared to placebo, increased throw distance (3.0 ± 5.1%, p = 0.048) and speed release (5.7 ± 8.7%, p = 0.03) for the complete throw, and distance (3.6 ± 4.4%, p = 0.01) and speed release (4.8 ± 7.4 %, p = 0.01) for the modified throw. Caffeine ingestion did not significantly improve jump height (1.1 ± 4.3%, p = 0.28), although it improved force and power on braking and the propulsive phases of the CMJ ( p < 0.05). Caffeine only increased the prevalence of activeness ( p < 0.05)., Conclusions: An acute moderate dose of caffeine enhanced hammer and discus throw performance in well-trained throwers during a simulated competitive setting, with minimal adverse side effects.

This study aimed to analyze the placebo effect associated with caffeine ingestion on running performance., Methods: Thirteen recreationally trained males in long-distance running (age: 38.5 ± 11.9 years, 11.0 ± 8.8 years of running experience) performed a 6 min time trial test in each experimental condition (caffeine-informed/placebo ingested (placebo) and non-ingested (control)) separated by 7 days. The total distance covered was measured, and partial times of each 400 m were used to analyze the pacing strategy. Heart rate and kinematic variables were recorded for each split. In addition, the rate of perceived exertion and prevalence of caffeine side effects was measured using questionnaires., Results: Placebo ingestion improved running performance in the 6 min time trial test (1668 ± 139 m placebo vs. 1642 ± 158 m control, t = 2.49; p = 0.03; moderate ES = 0.69), while pacing, heart rate, RPE, and kinematic variables were similar between conditions ( p > 0.05 in all cases). Minor side effects were reported., Conclusions: Beliefs of caffeine ingestion can improve running performance at speeds around maximal aerobic speed in recreationally trained runners without affecting pacing strategy so this "nutritional" strategy could be useful in competition scenarios. As a practical application, recreationally trained runners could improve ≈5 s in 1500 m or mile competitions.

Introduction/purpose: Previous results about shoe longitudinal bending stiffness (LBS) and running economy (RE) show high variability. This study aimed to assess the effects of shoes with increased LBS on RE and performance in trained and national runners., Methods: Twenty-eight male runners were divided into two groups according to their 10-km performance times (trained, 38-45 min and national runners, <34 min). Subjects ran 2 × 3 min (at 9 and 13 km·h -1 for trained, and 13 and 17 km·h -1 for national runners) with an experimental shoe with carbon fiber plate to increase the LBS (Increased LBS) and a control shoe (without carbon fiber plate). We measured energy cost of running (W·kg -1 ) and spatiotemporal parameters in visit one and participants performed a 3000 m time trial (TT) in two successive visits., Results: Increased LBS improved RE in the trained group at slow (11.41 ± 0.93 W·kg -1 vs 11.86 ± 0.93 W·kg -1 ) and fast velocity (15.89 ± 1.24 W·kg -1 vs 16.39 ± 1.24 W·kg -1 ) and only at the fast velocity in the national group (20.35 ± 1.45 W·kg -1 vs 20.78 ± 1.18 W·kg -1 ). The improvements in RE were accompanied by different changes in biomechanical variables between groups. There were a similar improvement in the 3000 m TT test in Increased LBS for trained (639 ± 59 vs 644 ± 61 s in control shoes) and national runners (569 ± 21 vs 574 ± 21 s in control shoes) with more constant pace in increased LBS compared with control shoes in both groups., Conclusions: Increasing shoe LBS improved RE at slow and fast velocities in trained runners and only at fast velocity in national runners. However, the 3000 m TT test improved similarly in both levels of runners with increased LBS. The improvements in RE are accompanied by small modifications in running kinematics that could explain the difference between the different levels of runners., (Copyright © 2023 by the American College of Sports Medicine.)

This overview review aimed to describe the evolution of the characteristics of the research on caffeine effects on strength. A total of 189 experimental studies with 3459 participants were included. The median sample size was 15 participants, with an over-representation of men vs. women (79.4 vs. 20.6%). Studies on young participants and elders were scarce (4.2%). Most studies tested a single dose of caffeine (87.3%), while 72.0% used doses adjusted to body mass. Single-dose studies ranged from 1.7 to 7 mg/kg (4.8 ± 1.4 mg/kg), while dose-response studies ranged from 1 to 12 mg/kg. Caffeine was mixed with other substances in 27.0% of studies, although only 10.1% of studies analyzed the caffeine interaction with these substances. Capsules (51.9%) and beverages (41.3%) were the most common forms of caffeine administration. Similar proportions of studies focused on upper (24.9%) or lower body strength 37.6% (37.6% both). Participants' daily intake of caffeine was reported in 68.3% of studies. Overall, the pattern in the study of caffeine's effects on strength performance has been carried out with experiments including 11-15 adults, using a single and moderate dose of caffeine adjusted to participants' body mass in the form of a capsule.

In Spain, students pursuing a career in athletic training, physical education, or scientific evaluation of sports enroll in a bachelor’s degree in sports sciences. This degree provides knowledge and skills in a broad array of sports settings and promotes research-based interdisciplinary knowledge. However, the student’s syllabus rarely includes specific academic training on anti-doping regulations or doping prevention. The purpose of this study was to assess the anti-doping knowledge of the students undertaking a bachelor’s degree in sports sciences in Spanish universities. One thousand two hundred and thirty-three bachelor students in sport science (907 males, 322 females, and 4 participants with non-binary sex) from 26 Spanish universities completed a validated questionnaire about general anti-doping knowledge. The questionnaire is an adapted version of the Play True Quiz of the World Anti-Doping Agency and contains 37 multiple-choice questions. The score obtained in the questionnaire was transformed into a 0−100-point scale. The questionnaire was distributed among students within each university by a faculty member and it was filled out online. Students obtained a score of 65.8 ± 10.10 points (range = 32−92 points). There was an effect of the course in the score obtained (p < 0.001). Students of the first course (63.6 ± 9.5 points) had lower scores than the remaining courses (p < 0.037) while the students of the fourth course obtained the highest scores (68.7 ± 9.5 points; p < 0.019). The students with an itinerary on sports performance were the respondents with the highest anti-doping knowledge (67.2 ± 10.2) points, followed by the students with an itinerary on health (66.7 ± 9.5 points). The knowledge of basic anti-doping rules and doping prevention strategies of the bachelor students in sports sciences in Spain was suboptimal. Increasing doping prevention information in the syllabus of the bachelor’s degree in sports sciences is essential as these future professionals will directly work with populations at risk of doping.

The aim of this investigation was to determine the effect of a moderate dose of caffeine (3 mg/kg/b.m.) on muscular power and strength and shot put performance in trained athletes., Methods: Thirteen shot putters (eight men and five women) participated in a double-blind, placebo-controlled, randomized experiment. In two different trials, participants ingested either 3 mg/kg/b.m. of caffeine or a placebo. Forty-five min after substance ingestion, athletes performed a handgrip dynamometry test, a countermovement jump (CMJ), a squat jump (SJ), and a maximum-velocity push-up. The athletes also performed three types of throws: a backwards throw, a standing shot put and a complete shot put., Results: In comparison with the placebo, caffeine ingestion increased CMJ height (32.25 ± 7.26 vs . 33.83 ± 7.72 cm, respectively; effect size (ES) = 0.82, p = 0.012; +5.0%;) and SJ height (29.93 ± 7.88 vs . 31.40 ± 7.16 cm; ES = 0.63, p = 0.042; +6.4%) and distance in the standing shot put (10.27 ± 1.77 m vs . 10.55 ± 1.94 m; ES = 0.87, p = 0.009; +2.6%). However, caffeine ingestion did not increase strength in the handgrip test, power in the ballistic push-up, or distance in the backwards throw (all p > 0.05). Shot put performance changed from 11.24 ± 2.54 to 11.35 ± . 2.57 m (ES = 0.33, p = 0.26; +1.0%), although the difference did not reach statistically significant differences. Caffeine ingestion did not increase the prevalence of side effects (nervousness, gastrointestinal problems, activeness, irritability, muscular pain, headache, and diuresis) in comparison with the placebo (p > 0.05)., Conclusion: In summary, caffeine ingestion with a dose equivalent to 3 mg/kg/b.m. elicited moderate improvements in several aspects of physical performance in trained shot putters but with a small effect on distance in a complete shot put., Competing Interests: The authors declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; and no other relationships or activities that could appear to have influenced the submitted work., (© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.)

We aimed to analyze the number and distribution of doping control tests in which a banned substance was reported (i.e., adverse analytical finding) in aquatics. The analysis was performed by using the data provided by the WADA Testing Figure Reports from 2015 to 2019. A total of 79,956 doping control tests were analyzed. Sprint swimming, middle-distance swimming and water polo were the disciplines with the highest number of doping control tests. However, there were no differences in the frequency of adverse findings among disciplines (overall, ∼0.56%, from 0.13 in artistic swimming to 0.76% in sprint swimming). Sprinters and long-distance swimmers presented a higher frequency of beta-2-agonists than the remaining aquatic disciplines (p < 0.05). These results indicate that the type of prohibited substances employed is strongly influenced by the intrinsic characteristics of each aquatic discipline.

Purpose: Caffeine is widely considered an ergogenic aid to increase anaerobic performance although most of this evidence is supported by investigations with only male samples. To date, it is unknown if the ergogenic effect of caffeine on anaerobic performance is of similar magnitude in men and women athletes. The aim of this study was to determine the magnitude of the ergogenic effect of caffeine on the Wingate test in men and women., Methods: In a double-blind, placebo-controlled, cross-over experimental trial, ten women athletes and ten men athletes performed a 15-s adapted version of the Wingate test after ingesting 3 mg of caffeine per kg of body mass or a placebo (cellulose)., Results: In comparison to the performance obtained in the 15-s Wingate test with a placebo, caffeine increased peak power in men (9.9 ± 0.8 vs. 10.1 ± 0.8 W/kg, p < 0.01, d = 0.26) and in women (8.8 ± 0.9 vs. 9.1 ± 0.8 W/kg, p = 0.04, d = 0.30). Caffeine was also effective to increase the mean power in men (8.9 ± 0.7 vs. 9.0 ± 0.7 W/kg, p = 0.01, d = 0.21) and women (8.1 ± 0.7 vs. 8.3 ± 0.7 W/kg, p = 0.01, d = 0.27). The ergogenic effect of caffeine on the 15-s Wingate peak power (2.3 ± 3.2% in men and 3.2 ± 2.8% in women; p = 0.46) and mean power (2.0 ± 1.7% and 2.4 ± 2.3%, respectively; p = 0.93) was of similar magnitude in both sexes., Conclusion: Acute ingestion of 3 mg kg -1 of caffeine enhanced peak and mean cycling power during a 15-s adapted version of the Wingate test in men and women and the ergogenic effect was of similar magnitude in both sexes. This information suggests that both men and women athletes might obtain similar benefits from caffeine supplementation during anaerobic exercise., (© 2021. Springer-Verlag GmbH, DE part of Springer Nature.)

This investigation presents a comparison of calcaneus bone stiffness of endurance runners of different ages and age-matched controls. We found that there was an age-associated decline in calcaneus bone stiffness in the control group while endurance runners prevented this decline, with a higher effect as the participants increased their age., Purpose: Previous investigations have found that endurance runners have higher bone mineral density and other bone quality variables in mechanically loaded bones. However, it is unknown if endurance running might counteract the decline in bone stiffness that occurs with age. The purpose of this study was to compare calcaneus bone stiffness of endurance runners of different ages to age-matched controls., Methods: In a descriptive cross-sectional study, 182 endurance-trained male runners and 116 healthy untrained male controls underwent an ultrasonographic assessment of the calcaneus bone in the right and left heels. Calcaneal bone stiffness was calculated from assessments of the broadband ultrasound attenuation and the speed of sound., Results: The line of best fit for the association between age and calcaneus stiffness was different between marathoners and controls (Z =  - 2.1, P = 0.02). A two-way ANCOVA (condition × age) with body mass, and body mass index as covariates, revealed that there were main effects of condition (F = 26.8, P < 0.01) and age (F = 4.2, P < 0.01) for calcaneus stiffness, with a significant interaction between these two factors (F = 2.8, P = 0.03). The post hoc analysis revealed that calcaneus stiffness was significantly higher in marathoners of 40-44 years (121.5 ± 18.2 vs 101.1 ± 21.3 arbitrary units [A.U.], P = 0.01), 45-49 years (121.5 ± 19.7 vs 104.3 ± 13.4 A.U., P = 0.04), and > 50 years (111.2 ± 17.9 vs 92.4 ± 16.0 A.U., P < 0.01) than their untrained counterparts of the same age with no statistically significant differences in the remaining age groups., Conclusion: Endurance runners of > 40 years had higher values of calcaneus stiffness than controls, providing evidence to support the potential effect of endurance running to reduce the age-related decline on calcaneus bone stiffness.

Previous research has identified acute caffeine intake as an effective ergogenic aid to enhance velocity and power during bench press exercise. However, no previous investigation has analyzed the effects of chronic intake of caffeine on training adaptations induced by bench press strength training. Thus, the aim of this investigation was to determine the effects of pre-exercise caffeine intake on training adaptations induced by a bench press training protocol. Using a double-blind, randomized experimental design, 16 healthy participants underwent a bench press training protocol for 4 weeks (12 sessions). Seven participants ingested a placebo and nine participants ingested 3 mg/kg/BM of caffeine before each training session. Three days before, and 3 days after the completion of the training protocol, participants performed a one-repetition maximum (1RM) bench press and force-velocity test (from 10 to 100% 1RM). From comparable pre-training values, the strength training similarly increased 1RM in the caffeine and placebo groups (+13.5 ± 7.8% vs. +11.3 ± 5.3%, respectively; p = 0.53). In the caffeine group, the strength training induced a higher mean velocity at 40%, (0.81 ± 0.08 vs. 0.90 ± 0.14 m/s), 60% (0.60 ± 0.06 vs. 0.65 ± 0.06 m/s), 70% (0.47 ± 0.05 vs. 0.55 ± 0.06 m/s), 80% (0.37 ± 0.06 vs. 0.45 ± 0.05 m/s), 90% (0.26 ± 0.07 vs. 0.34 ± 0.06 m/s), and 100% 1RM (0.14 ± 0.04 vs. 0.25 ± 0.05 m/s; p < 0.05) while the increases in the placebo group were evident only at 30 (0.95 ± 0.06 vs. 1.03 ± 0.07 m/s), 70% (0.51 ± 0.03 vs. 0.57 ± 0.05 m/s) and 80% 1RM (0.37 ± 0.06 vs. 0.45 ± 0.05 m/s) ( p < 0.05). The placebo group only increased peak velocity at 60 and 70% 1RM ( p < 0.05) while peak velocity increased at 10%, and from 30 to 100% 1RM in the caffeine group ( p < 0.05). The use of 3 mg/kg/BM of caffeine before exercise did not modify improvements in 1RM obtained during a 4 week bench press strength training program but induced more muscle performance adaptations over a wider range of load., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Giráldez-Costas, Ruíz-Moreno, González-García, Lara, Del Coso and Salinero.)

The aim of this investigation was to describe the outcomes of the adverse analytical findings in different Olympic sports. The data included were gathered from the World Anti-Doping Agency Anti-doping Rule Violations Reports (2013-2017). Weightlifting (78.1 ± 9.4%) wrestling (73.2 ± 18.5%) and volleyball (68.3 ± 18.7%) were the sports with the highest proportion of cases that ended in an antidoping sanction. Gymnastics (45.1 ± 10.1%), triathlon (32.6 ± 11.9%) and shooting (29.9 ± 14.1%) were the sports with a higher frequency of cases that were not sanctioned due to medical reasons. Gymnastics (22.4 ± 18.4%), boxing (23.2 ± 16.0%) and taekwondo (17.3.1 ± 16.4%) presented the highest proportion of cases that are still pending resolution. The proportion of cases that ended in no sanction was higher in fencing (26.2 ± 22.7%), skating (23.6 ± 35.1%) and tennis (18.6 ± 26.5%). These results indicate that the sanctions derived from antidoping rule violations were not uniform in all sports disciplines.

Purpose: This study aimed to identify and describe the time course of tolerance to the most common caffeine-induced side effects., Methods: Eleven participants took part in a crossover, double-blind placebo-controlled experimental design. In one phase, participants ingested 3 mg/kg/day of caffeine for 20 days, while in another phase, they ingested a placebo. Resting heart rate and blood pressure were measured three times per week during each 20-day phase and a quantitative survey was used to categorise the magnitude of side effects., Results: In the pairwise comparison with the placebo, the ingestion of caffeine increased systolic (+ 7.8 ± 10.1%, P < 0.05) and diastolic blood pressure (+ 6.4 ± 12.9% P < 0.05) for the first 8 days of ingestion, but then this effect became attenuated for both outcomes (on day 20, - 1.1 ± 4.3% and + 0.9 ± 9.6%, respectively). The ingestion of caffeine did not affect heart rate at any time point. Caffeine increased the feelings of nervousness and vigour and the rating of gastrointestinal complaints, insomnia and diuresis at several time points in the treatment (P < 0.05) and they did not disappear after 20 days of ingestion., Conclusions: The daily intake of 3 mg/kg of caffeine induced a meaningful elevation in arterial blood pressure that disappeared after 8 days. However, other caffeine-induced effects such as increased nervousness and vigour, irritability, insomnia and diuresis remained after 20 days of consecutive caffeine ingestion. Although there was clear tolerance to the effect of caffeine on blood pressure, the persistence of other side effects suggests the inconvenience of maintaining a chronic caffeine intake, at least at the dose of 3 mg/kg/day.

Previous investigations have established the ergogenic effect of caffeine on maximal muscle strength, power output and strength-endurance. However, these investigations used testing protocols that do not replicate the structure of a regular strength training session. Thus, the aim of this study was to investigate the effect of acute caffeine ingestion on muscle performance during a simulated velocity-based training workout. In a double-blind, randomized and counterbalanced experiment, 12 participants performed two experimental trials after ingesting 3 mg/kg/b.m. of caffeine or a placebo. The trials consisted of 4 sets of 8 repetitions of the bench press exercise at 70% of their one-repetition maximum performed at maximal velocity. Bar velocity was recorded with a rotatory encoder and force, power output and work were calculated. Regarding the whole workout, caffeine increased mean bar velocity (+7.8%; p=0.002), peak bar velocity (+8.7%; p=0.006), mean force (+1.5%; p=0.002), mean power output (+10.1%; p=0.003) and peak power output (+8.2%; p=0.004) when compared to the placebo. The total work performed in the caffeine trial was superior to the placebo trial (7.01±2.36 vs 6.55±2.20 kJ, p=0.001). These results suggest that the acute intake of 3 mg/kg/b.m. of caffeine before a velocity-based strength workout increased muscle performance and the total work performed across the whole training session. Thus, caffeine can be considered as an effective strategy to enhance muscle performance during the bench press training sessions., (© 2020 Verónica Giráldez-Costas, Jaime González-García, Beatriz Lara, Juan Del Coso, Michal Wilk, Juan José Salinero, published by Sciendo.)

The aim of this investigation was to perform a systematic review and meta-analysis to determine the efficacy of the acute ingestion of caffeine (from 3 to 6 mg/kg) to increase performance on variables related to team sports. A systematic review was performed in scientific databases from January to April 2018. All studies included had cross-over experimental designs comparing caffeine to an identical placebo condition. A meta-analysis was performed using the random effects model and pooled standardized mean differences (Glass's Δ). Thirty-four studies published between 2001 and 2018 were included in the analysis. The meta-analysis revealed that caffeine increased single (Δ;95% confidence intervals = 0.19;0.14-0.25; p < 0.01) and repeated jump height (0.29;0.16-0.42; p < 0.01), single (0.16;0.02-0.30; p = 0.03) and repeated sprint velocity (0.14;0.03-0.25; p = 0.02), and reduced the time to complete agility tests (0.41;0.04-0.77; p = 0.03). During team sport matches, caffeine increased total running distance (0.41;0.20-0.62; p < 0.01), distance covered at sprint velocity (0.36;0.12-0.59; p < 0.01) and the number of sprints (0.44;0.18-0.69; p < 0.01). The acute ingestion of a moderate dose of caffeine had a small but significant positive effect on several aspects related to physical performance in team sports.

The ergogenicity of caffeine on several exercise and sport situations is well-established. However, the extent of the ergogenic response to acute caffeine ingestion might greatly vary among individuals despite using the same dosage and timing. The existence of one or several individuals that obtained minimal ergogenic effects or even slightly ergolytic effects after caffeine intake (i.e., non-responders) has been reported in several previous investigations. Nevertheless, the concept non-responding to caffeine, in terms of physical performance, relies on investigations based on the measurement of one performance variable obtained once. Recently it has been suggested that correct identification of the individual ergogenic effect induced by caffeine intake requires the repeated measurement of physical performance in identical caffeine⁻placebo comparisons. In this communication, we present data from an investigation where the ergogenic effect of acute caffeine intake (3 mg/kg) was measured eight times over a placebo in the same individuals and under the same conditions by an incremental cycling test to volitional fatigue and an adapted version of the Wingate cycling test. The ergogenic response to caffeine varied from 9% to 1% among individuals, but all participants increased both cycling power in the incremental test and Wingate mean power at least three to eight times out of eight the caffeine⁻placebo comparisons. These data expand the suggestion of a minimal occurrence of caffeine non-responders because it shows that all individuals responded to caffeine when caffeine is compared to a placebo on multiple and repeated testing sessions.

The ergogenic effect of caffeine is well-established, but the extent of its consumption in sport is unknown at the present. The use of caffeine was considered "prohibited" until 2004, but this stimulant was moved from the List of Prohibited Substances to the Monitoring Program of the World Anti-Doping Agency to control its use by monitoring urinary caffeine concentration after competition. However, there is no updated information about the change in the use of caffeine as the result of its inclusion in the Monitoring Program. The aim of this study was to describe the changes in urine caffeine concentration from 2004 to 2015. A total of 7488 urine samples obtained in official competitions held in Spain and corresponding to athletes competing in Olympic sports (2788 in 2004, 2543 in 2008, and 2157 in 2015) were analyzed for urine caffeine concentration. The percentage of samples with detectable caffeine (i.e., >0.1 μg/mL) increased from ~70.1%, in 2004⁻2008 to 75.7% in 2015. The median urine caffeine concentration in 2015 (0.85 μg/mL) was higher when compared to the median value obtained in 2004 (0.70 μg/mL; p < 0.05) and in 2008 (0.70 μg/mL; p < 0.05). The urine caffeine concentration significantly increased from 2004 to 2015 in aquatics, athletics, boxing, judo, football, weightlifting, and rowing ( p < 0.05). However, the sports with the highest urine caffeine concentration in 2015 were cycling, athletics, and rowing. In summary, the concentration of caffeine in the urine samples obtained after competition in Olympic sports in Spain increased from 2004 to 2015, particularly in some disciplines. These data indicate that the use of caffeine has slightly increased since its removal from the list of banned substances, but urine caffeine concentrations suggest that the use of caffeine is moderate in most sport specialties. Athletes of individual sports or athletes of sports with an aerobic-like nature are more prone to using caffeine in competition.

The ergogenic effect of acute caffeine ingestion has been widely investigated; however, scientific information regarding tolerance to the performance benefits of caffeine, when ingested on a day-to-day basis, is scarce. The aim of this investigation was to determine the time course of tolerance to the ergogenic effects of a moderate dose of caffeine. Eleven healthy active participants took part in a cross-over, double-blind, placebo-controlled experiment. In one treatment, they ingested 3 mg/kg/day of caffeine for 20 consecutive days while in another they ingested a placebo for 20 days. Each substance was administered daily in an opaque unidentifiable capsule, and the experimental trials started 45 min after capsule ingestion. Two days before, and three times per week during each 20-day treatment, aerobic peak power was measured with an incremental test to volitional fatigue (25 W/min) and aerobic peak power was measured with an adapted version of the Wingate test (15 s). In comparison to the placebo, the ingestion of caffeine increased peak cycling power in the incremental exercise test by ~4.0 ±1.3% for the first 15 days (P<0.05) but then this ergogenic effect lessened. Caffeine also increased peak cycling power during the Wingate test on days 1, 4, 15, and 18 of ingestion by ~4.9 ±0.9% (P<0.05). In both tests, the magnitude of the ergogenic effect of caffeine vs. placebo was higher on the first day of ingestion and then progressively decreased. These results show a continued ergogenic effect with the daily ingestion of caffeine for 15-18 days; however, the changes in the magnitude of this effect suggest progressive tolerance., Competing Interests: The authors have declared that no competing interests exist.

Purpose: The aim of this investigation was to analyze the influence of the genetic variations of the -163C>A polymorphism of the CYP1A2 gene on the ergogenic effects of caffeine in elite basketball players., Methods: Nineteen elite basketball players (10 men and 9 women) ingested 3 mg⋅kg-1 of caffeine or a placebo 60 min before performing 10 repetitions of the following series: the Abalakov jump test followed by the Change-of-Direction and Acceleration Test (CODAT). The players then competed in a 20-min simulated basketball game. Self-perceived performance and side effects were recorded by questionnaires after the trials. The effects of caffeine on basketball performance were established according to players' CYP1A2 genotype (rs762551): AA homozygotes (n = 10) and C-allele carriers (n = 9)., Results: In the 10 repetitions, caffeine increased Abalakov jump height by a mean of 2.9±3.6% in AA homozygotes (p = 0.03) while this effect did not reach statistical significance for C-allele carriers (2.3 ± 6.8%; p = 0.33). Caffeine did not affect sprint time in the CODAT test in either genotype group but it increased the number of impacts performed during the simulated game in both AA homozygotes (4.1 ± 5.3%; p = 0.02) and C-allele carriers (3.3 ± 3.2%; p = 0.01). During the 24 h following the test, AA homozygotes tended to experience increased insomnia with caffeine while C-allele carriers did not present this effect. The remaining variables were unaffected by the genotype., Conclusion: The CYP1A2 -163C>A polymorphism minimally altered the ergogenicity derived from the consumption of a moderate dose of caffeine in elite basketball players.

The aim of this study was to determine the effect of caffeine intake on overall basketball performance in experienced players. A double-blind, placebo-controlled, randomized experimental design was used for this investigation. In two different sessions separated by one week, 20 experienced basketball players ingested 3 mg of caffeine/kg of body mass or a placebo. After 60 min, participants performed 10 repetitions of the following sequence: Abalakov jump, Change-of-Direction and Acceleration Test (CODAT) and two free throws. Later, heart rate, body impacts and game statistics were recorded during a 20-min simulated basketball game. In comparison to the placebo, the ingestion of caffeine increased mean jump height (37.3 ± 6.8 vs. 38.2 ± 7.4 cm; p = 0.012), but did not change mean time in the CODAT test or accuracy in free throws. During the simulated game, caffeine increased the number of body impacts (396 ± 43 vs. 410 ± 41 impacts/min; p < 0.001) without modifying mean or peak heart rate. Caffeine also increased the performance index rating (7.2 ± 8.6 vs. 10.6 ± 7.1; p = 0.037) during the game. Nevertheless, players showed a higher prevalence of insomnia (19.0 vs. 54.4%; p = 0.041) after the game. Three mg of caffeine per kg of body mass could be an effective ergogenic substance to increase physical performance and overall success in experienced basketball players., Competing Interests: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Purpose: Exertional rhabdomyolysis can occur in individuals performing various types of exercise but it is unclear why some individuals develop this condition while others do not. Previous investigations have determined the role of several single nucleotide polymorphisms (SNPs) to explain inter-individual variability of serum creatine kinase (CK) concentrations after exertional muscle damage. However, there has been no research about the interrelationship among these SNPs. The purpose of this investigation was to analyze seven SNPs that are candidates for explaining individual variations of CK response after a marathon competition (ACE = 287bp Ins/Del, ACTN3 = p.R577X, CKMM = NcoI, IGF2 = C13790G, IL6 = 174G>C, MLCK = C37885A, TNFα = 308G>A)., Methods: Using Williams and Folland's model, we determined the total genotype score from the accumulated combination of these seven SNPs for marathoners with a low CK response (n = 36; serum CK <400 U·L-1) vs. marathoners with a high CK response (n = 31; serum CK ≥400 U·L-1)., Results: At the end of the race, low CK responders had lower serum CK (290±65 vs. 733±405 U·L-1; P<0.01) and myoglobin concentrations (443±328 vs. 1009±971 ng·mL-1, P<0.01) than high CK responders. Although the groups were similar in age, anthropometric characteristics, running experience and training habits, total genotype score was higher in low CK responders than in high CK responders (5.2±1.4 vs. 4.4±1.7 point, P = 0.02)., Conclusion: Marathoners with a lower CK response after the race had a more favorable polygenic profile than runners with high serum CK concentrations. This might suggest a significant role of genetic polymorphisms in the levels of exertional muscle damage and rhabdomyolysis. Yet other SNPs, in addition to exercise training, might also play a role in the values of CK after damaging exercise.

Purpose: Exercise-induced muscle damage has been identified as one of the main causes of the progressive decrease in running and muscular performance in marathoners. The aim of this investigation was to determine the influence of the ACTN3 genotype on exercise-induced muscle damage produced during a marathon., Methods: Seventy-one experienced runners competed in a marathon race. Before and after the race, a sample of venous blood was obtained and maximal voluntary leg muscle power was measured during a countermovement jump. In the blood samples, the ACTN3 genotype (R577X) and the changes in serum creatine kinase and myoglobin concentrations were measured. Data from RX heterozygotes and XX mutant homozygotes were grouped as X allele carriers and compared to RR homozygotes., Results: At the end of the race, X allele carriers presented higher serum myoglobin (774 ± 852 vs 487 ± 367 U L -1 ; P = 0.02) and creatine kinase concentrations (508 ± 346 vs 359 ± 170 ng mL -1 ; P = 0.04) than RR homozygotes. Pre-to-post-race maximal voluntary leg muscle power reduction was more pronounced in X allele carriers than RR homozygotes (-34.4 ± 16.1 vs -27.3 ± 15.4%; P = 0.05). X allele carriers self-reported higher levels of lower limb muscle pain (7 ± 2 vs 6 ± 2 cm; P = 0.02) than RR homozygotes at the end of the race., Conclusions: In comparison to RR homozygotes, X allele carriers for the R577X polymorphism of the ACTN3 gene presented higher values for typical markers of exercise-induced muscle damage during a competitive marathon. Thus, the absence of a functional α-actinin-3 produced by the X allele might induce higher levels of muscle breakdown during prolonged running events.

Purpose: Alpha-actinin-3, encoded by the ACTN3 gene, is an actin-binding protein with an important role in myofibril contraction and muscle force output. In humans, there is a relatively common deficiency of the α-actinin-3 due to homozygosity in a polymorphism of the ACTN3 gene (R577X, rs1815739), that has been related to decreased resistance to strain during voluntary muscle contractions. The purpose of this study was to investigate the influence of the ACTN3 genotype on the level of exercise-induced muscle damage attained by 23 experienced triathletes during an official half-ironman competition., Methods: Before and after the race, a sample of venous blood was obtained and jump height was measured during a countermovement jump. The changes in serum creatine kinase (CK-MM isoform) were measured in the blood samples and muscle pain was measured with a visual analogue scale (0-10 cm). Data from RX heterozygotes and XX mutant homozygotes were grouped as X-allele carriers (n = 13) and compared to RR homozygotes (n = 10)., Results: Race time was very similar between groups (313 ± 31 vs. 313 ± 25 min; P = 0.45); however, pre-to-post-competition reduction in jump height was greater in X-allele carriers than RR homozygotes (-18.4 ± 11.4 vs. -8.2 ± 6.9%; P = 0.04). At the end of the race, X-allele carriers presented higher serum CK-MM concentrations (682 ± 144 vs. 472 ± 269 U/L; P = 0.03), and there was also a tendency for higher self-reported values of lower limb muscle pain (7.7 ± 1.1 vs. 6.3 ± 2.3 cm; P = 0.06)., Conclusions: X-allele triathletes in the ACTN3 R577X polymorphism presented greater signs of exercise-induced muscle damage during a half-ironman race than RR homozygotes.

Myosin light chain kinase (MLCK) phosphorylates the regulatory light chain (RLC) of myosin producing increases in force development during skeletal muscle contraction. It has been suggested that MLCK gene polymorphisms might alter RLC phosphorylation thereby decreasing the ability to produce force and to resist strain during voluntary muscle contractions. Thus, the genetic variations in the MLCK gene might predispose some individuals to higher values of muscle damage during exercise, especially during endurance competitions. The aim of this investigation was to determine the influence of MLCK genetic variants on exercise-induced muscle damage produced during a marathon. Sixty-seven experienced runners competed in a marathon race. The MLCK genotype (C37885A) of these marathoners was determined. Before and after the race, a sample of venous blood was obtained to assess changes in serum myoglobin concentrations and leg muscle power changes were measured during a countermovement jump. Self-reported leg muscle pain and fatigue were determined by questionnaires. A total of 59 marathoners (88.1%) were CC homozygotes and 8 marathoners (11.9%) were CA heterozygotes. The two groups of participants completed the race with a similar time (228 ± 33 vs 234 ± 39 min; P = 0.30) and similar self-reported values for fatigue (15 ± 2 vs 16 ± 2 A.U.; P = 0.21) and lower-limb muscle pain (6.2 ± 1.7 vs 6.6 ± 1.8 cm; P = 0.29). However, CC marathoners presented higher serum myoglobin concentrations (739 ± 792 vs 348 ± 144 μg·mL-1; P = 0.03) and greater pre-to-post- race leg muscle power reduction (-32.7 ± 15.7 vs -21.2 ± 21.6%; P = 0.05) than CA marathoners. CA heterozygotes for MLCK C37885A might present higher exercise-induced muscle damage after a marathon competition than CC counterparts.

Background: Sodium (Na(+)) intake during exercise aims to replace the Na(+) lost by sweat to avoid electrolyte imbalances, especially in endurance disciplines. However, Na(+) needs can be very different among individuals because of the great inter-individual variability in sweat electrolyte concentration. The aim of this investigation was to determine sweat electrolyte concentration in a large group of marathoners., Methods: A total of 157 experienced runners (141 men and 16 women) completed a marathon race (24.4 ± 3.6 °C and 27.7 ± 4.8 % of humidity). During the race, sweat samples were collected by using sweat patches placed on the runners' forearms. Sweat electrolyte concentration was measured by using photoelectric flame photometry., Results: As a group, sweat Na(+) concentration was 42.9 ± 18.7 mmol·L(-1) (minimal-maximal value = 7.0-95.5 mmol·L(-1)), sweat Cl(-) concentration was 32.2 ± 15.6 mmol·L(-1) (7.3-90.6 mmol·L(-1)) and sweat K(+) concentration was 6.0 ± 0.9 mmol·L(-1) (3.1-8.0 mmol·L(-1)). Women presented lower sweat Na(+) (33.9 ± 12.1 vs 44.0 ± 19.1 mmol·L(-1); P = 0.04) and sweat Cl(-) concentrations (22.9 ± 10.5 vs 33.2 ± 15.8 mmol·L(-1); P = 0.01) than men. A 20 % of individuals presented a sweat Na(+) concentration higher than 60 mmol·L(-1) while this threshold was not surpassed by any female marathoner. Sweat electrolyte concentration did not correlate to sweat rate, age, body characteristics, experience or training. Although there was a significant correlation between sweat Na(+) concentration and running pace (r = 0.18; P = 0.03), this association was weak to interpret that sweat Na(+) concentration increased with running pace., Conclusions: The inter-individual variability in sweat electrolyte concentration was not explained by any individual characteristics except for individual running pace and sex. An important portion (20 %) of marathoners might need special sodium intake recommendations due to their high sweat salt losses.

The aim of this investigation was to determine the efficacy of a caffeine-containing energy drink to improve physical performance of elite field hockey players during a game. On 2 days separated by a week, 13 elite field hockey players (age and body mass = 23.2 ± 3.9 years and 76.1 ± 6.1 kg) ingested 3 mg of caffeine per kg of body mass in the form of an energy drink or the same drink without caffeine (placebo drink). After 60 min for caffeine absorption, participants played a simulated field hockey game (2 × 25 min). Individual running pace and instantaneous speed during the game were assessed using GPS devices. The total number of accelerations and decelerations was determined by accelerometry. Compared with the placebo drink, the caffeinated energy drink did not modify the total distance covered during the game (6,035 ± 451 m and 6,055 ± 499 m, respectively; p = .87), average heart rate (155 ± 13 beats per min and 158 ± 18 beats per min, respectively; p = .46), or the number of accelerations and decelerations (697 ± 285 and 618 ± 221, respectively; p = .15). However, the caffeinated energy drink reduced the distance covered at moderate-intensity running (793 ± 135 and 712 ± 116, respectively; p = .03) and increased the distance covered at high-intensity running (303 ± 67 m and 358 ± 117 m; p = .05) and sprinting (85 ± 41 m and 117 ± 55 m, respectively; p = .02). Elite field hockey players can benefit from ingesting caffeinated energy drinks because they increase the running distance covered at high-intensity running and sprinting. Increased running distance at high speed might represent a meaningful advantage for field hockey performance.

Purpose: The aim of this investigation was to determine the influence of endurance running on calcaneus bone stiffness in male and female runners., Methods: A total of 122 marathoners (longer distance runners, men = 101; women = 21) and 81 half-marathon and 10-km runners (shorter distance runners; men = 48; women = 33), competing in an international running event, underwent an ultrasonographic assessment of the right and left calcaneus. Calcaneus bone stiffness was estimated using the measurements of the speed of sound (SOS) and broadband ultrasound attenuation (BUA). Seventy-five age-matched sedentary people served as the control group., Results: Male and female longer distance runners and shorter distance runners presented higher values than sedentary counterparts in SOS (P < 0.05), and calcaneus stiffness (P < 0.05). Although there were no significant differences between longer distance and shorter distance runners in the ultrasonographic variables, longer distance runners presented greater effects size in SOS (1.00 vs. 0.93 males; 1.10 vs. 0.77 females), BUA (0.62 vs. 0.25 males; 0.89 vs. 0.20 females) and calcaneus stiffness (0.88 vs. 0.66 males; 1.20 vs. 0.60 females) than shorter distance endurance runners., Conclusion: Calcaneus bone stiffness was higher in all endurance runners compared to a sedentary control population. The volume of ground reaction forces which occur during endurance running might induce the adaptation of the calcaneus bone.

P-Synephrine is a protoalkaloid widely used as an ergogenic aid in sports. This substance has been included in the World Anti-Doping Agency monitoring program, although scientific information about its effects on performance and athletes' well-being is scarce. The purpose of this investigation was to determine the effectiveness of p-synephrine to increase performance in sprint athletes. In a randomized and counterbalanced order, 13 experienced sprinters performed 2 acute experimental trials after the ingestion of p-synephrine (3 mg·kg(-1)) or after the ingestion of a placebo (control trial). Forty-five minutes after the ingestion of the substances, the sprinters performed a squat jump, a countermovement jump, a 15-s repeated jump test, and subsequently performed 60-m and 100-m simulated sprint competitions. Self-reported questionnaires were used to assess side-effect prevalence. In comparison with the control trial, the ingestion of p-synephrine did not change countermovement jump height (37.4 ± 4.2 vs 36.7 ± 3.3 cm, respectively; P = 0.52), squat jump height (34.4 ± 3.6 vs 33.9 ± 3.7 cm; P = 0.34), or average 15-s repeated jumps height (31.8 ± 4.1 vs 32.2 ± 3.6 cm; P = 0.18). P-Synephrine did not modify maximal running speed during the 60-m (9.0 ± 0.5 vs 9.0 ± 0.4 m·s(-1), respectively; P = 0.55) and 100-m sprint competitions (8.8 ± 0.5 vs 8.8 ± 0.5 m·s(-1), respectively; P = 0.92). The ingestion of p-synephrine did not alter the prevalence of headache, gastrointestinal discomforts, muscle pain, or insomnia during the hours following the tests. Acute consumption of 3 mg·kg(-1) of p-synephrine was ineffective to increase performance in competitive sprint athletes. Moreover, p-synephrine did not increase the occurrence of side effects after the competition.

The purpose of the study was to assess the occurrence of muscle damage after a simulated badminton match and its influence on physical and haematological parameters. Sixteen competitive male badminton players participated in the study. Before and just after a 45-min simulated badminton match, maximal isometric force and badminton-specific running/movement velocity were measured to assess muscle fatigue. Blood samples were also obtained before and after the match. The badminton match did not affect maximal isometric force or badminton-specific velocity. Blood volume and plasma volume were significantly reduced during the match and consequently haematite, leucocyte, and platelet counts significantly increased. Blood myoglobin and creatine kinase concentrations increased from 26.5 ± 11.6 to 197.3 ± 70.2 µg·L(-1) and from 258.6 ± 192.2 to 466.0 ± 296.5 U·L(-1), respectively. In conclusion, a simulated badminton match modified haematological parameters of whole blood and serum blood that indicate the occurrence of muscle fibre damage. However, the level of muscle damage did not produce decreased muscle performance.

This study investigated the effect of a caffeinated energy drink on various aspects of performance in sprint swimmers. In a randomised and counterbalanced order, fourteen male sprint swimmers performed two acute experimental trials after the ingestion of a caffeinated energy drink (3 mg/kg) or after the ingestion of the same energy drink without caffeine (0 mg/kg; placebo). After 60 min of ingestion of the beverages, the swimmers performed a countermovement jump, a maximal handgrip test, a 50 m simulated competition and a 45 s swim at maximal intensity in a swim ergometer. A blood sample was withdrawn 1 min after the completion of the ergometer test. In comparison with the placebo drink, the intake of the caffeinated energy drink increased the height in the countermovement jump (49.4 (SD 5.3) v. 50.9 (SD 5.2) cm, respectively; P<0.05) and maximal force during the handgrip test with the right hand (481 (SD 49) v. 498 (SD 43) N; P<0.05). Furthermore, the caffeinated energy drink reduced the time needed to complete the 50 m simulated swimming competition (27.8 (SD 3.4) v. 27.5 (SD 3.2) s; P<0.05), and it increased peak power (273 (SD 55) v. 303 (SD 49) W; P <0.05) and blood lactate concentration (11.0 (SD 2.0) v. 11.7 (SD 2.1) mM; P<0.05) during the ergometer test. The caffeinated energy drink did not modify the prevalence of insomnia (7 v. 7%), muscle pain (36 v. 36%) or headache (0 v. 7%) during the hours following its ingestion (P>0.05). A caffeinated energy drink increased some aspects of swimming performance in competitive sprinters, whereas the side effects derived from the intake of this beverage were marginal at this dosage.

The aim of this study was to investigate the relationship between changes in serum free amino acids, muscle fatigue and exercise-induced muscle damage during a half-ironman triathlon. Twenty-six experienced triathletes (age = 37.0 ± 6.8 yr; experience = 7.4 ± 3.0 yr) competed in a real half-ironman triathlon in which sector times and total race time were measured by means of chip timing. Before and after the race, a countermovement jump and a maximal isometric force test were performed, and blood samples were withdrawn to measure serum free amino acids concentrations, and serum creatine kinase levels as a blood marker of muscle damage. Total race time was 320 ± 37 min and jump height (-16.3 ± 15.2%, P < 0.001) and isometric force (-14.9 ± 9.8%; P = 0.007) were significantly reduced after the race in all participants. After the race, the serum concentration of creatine kinase increased by 368 ± 187% (P < 0.001). In contrast, the serum concentrations of essential (-27.1 ± 13.0%; P < 0.001) and non-essential amino acids (-24.4 ± 13.1%; P < 0.001) were significantly reduced after the race. The tryptophan/BCAA ratio increased by 42.7 ± 12.7% after the race. Pre-to-post changes in serum free amino acids did not correlate with muscle performance variables or post-race creatine kinase concentration. In summary, during a half-ironman triathlon, serum amino acids concentrations were reduced by > 20%. However, neither the changes in serum free amino acids nor the tryptophan/BCAA ratio were related muscle fatigue or muscle damage during the race.

Study Design: Case-control study; ecological study., Objectives: To examine the efficacy of wearing compression stockings to prevent muscle damage and to maintain running performance during a marathon competition., Background: Exercise-induced muscle damage has been identified as one of the main causes of the progressive decrease in running and muscular performance found during marathon races., Methods: Thirty-four experienced runners were pair-matched for age, anthropometric data, and best race time in the marathon, and randomly assigned to a control group (n = 17) of runners who wore conventional socks or to a group of runners who wore foot-to-knee graduated compression stockings (n = 17). Before and after the race, a sample of venous blood was obtained, and jump height and leg muscle power were measured during a countermovement jump. Serum myoglobin and creatine kinase concentrations were determined as blood markers of muscle fiber damage., Results: Total race time was not different between the control group and the compression stockings group (210 ± 23 and 214 ± 22 minutes, respectively; P = .58). Between the control group and the compression stockings group, postrace reductions in leg muscle power (-19.8% ± 17.7% versus -24.8% ± 18.4%, respectively; P = .37) and jump height (-25.3% ± 14.1% versus -32.5% . 20.4%, respectively; P = .27) were similar. At the end of the race, there were no differences between the control group and the compression stockings group in serum myoglobin (568 ± 347 ng·mL(-1) versus 573 ± 270 ng·mL(-1), respectively; P = .97) and creatine kinase concentration (390 ± 166 U·L(-1) versus 487 ± 227 U·L(-1), respectively; P = .16)., Conclusion: The use of compression stockings did not improve running pace and did not prevent exercise-induced muscle damage during the marathon. Wearing compression stockings during long-distance running events is an ineffective strategy to avoid the deleterious effects of muscle damage on running performance., Level of Evidence: Therapy, level 2b.

Purpose: The objective of this study is to determine the effects of a caffeine-containing energy drink on female volleyball players' performance., Methods: Thirteen elite female volleyball players ingested 3 mg·kg of caffeine with an energy drink or the same drink without caffeine (placebo drink) in a double-blind and randomized study. Then, participants performed the following: standing spike, jumping spike, spike jump, blocking jump, squat jump, countermovement jump, manual dynamometry, and the agility t-test. A simulated volleyball game was played, videotaped, and notated afterward., Results: In comparison to the placebo drink, the ingestion of the caffeinated energy drink increased the ball velocity in the standing spike (19.2 ± 2.1 vs 19.7 ± 1.9 m·s, P = 0.023) and in the jumping spike (17.9 ± 2.2 vs 18.8 ± 2.2 m·s, P = 0.038) and the jump height in the squat jump (28.1 ± 3.2 vs 29.4 ± 3.6 cm, P = 0.028), countermovement jump (32.0 ± 4.6 vs 33.1 ± 4.5 cm, P = 0.018), spike jump (43.3 ± 4.7 vs 44.4 ± 5.0 cm, P = 0.025), and block jump (35.2 ± 5.1 vs 36.1 ± 5.1 cm, P = 0.044). Furthermore, the caffeinated energy drink decreased the time needed to complete the agility t-test (11.1 ± 0.5 vs 10.9 ± 0.3 s, P = 0.036). During the game, the volleyball actions categorized as successful were more frequent with the caffeinated energy drink (34% ± 9% vs 45% ± 9%, P < 0.001), whereas imprecise actions decreased (28% ± 7% vs 14% ± 9%, P < 0.001) when compared with the placebo drink., Conclusion: Commercially available energy drinks can significantly improve physical performance in female volleyball players. Increased physical performance led to improved accuracy during an actual volleyball match.

The aim of this study was to investigate the effectiveness of a caffeinated energy drink to enhance physical performance in elite junior tennis players. In 2 different sessions separated by 1 wk, 14 young (16 ± 1 y) elite-level tennis players ingested 3 mg caffeine per kg body mass in the form of an energy drink or the same drink without caffeine (placebo). After 60 min, participants performed a handgrip-strength test, a maximal-velocity serving test, and an 8 × 15-m sprint test and then played a simulated singles match (best of 3 sets). Instantaneous running speed during the matches was assessed using global positioning (GPS) devices. Furthermore, the matches were videotaped and notated afterward. In comparison with the placebo drink, the ingestion of the caffeinated energy drink increased handgrip force by ~4.2% ± 7.2% (P = .03) in both hands, the running pace at high intensity (46.7 ± 28.5 vs 63.3 ± 27.7 m/h, P = .02), and the number of sprints (12.1 ± 1.7 vs 13.2 ± 1.7, P = .05) during the simulated match. There was a tendency for increased maximal running velocity during the sprint test (22.3 ± 2.0 vs 22.9 ± 2.1 km/h, P = .07) and higher percentage of points won on service with the caffeinated energy drink (49.7% ± 9.8% vs 56.4% ± 10.0%, P = .07) in comparison with the placebo drink. The energy drink did not improve ball velocity during the serving test (42.6 ± 4.8 vs 42.7 ± 5.0 m/s, P = .49). The preexercise ingestion of caffeinated energy drinks was effective to enhance some aspects of physical performance of elite junior tennis players.

The aim of this study was to investigate the effectiveness of a caffeine-containing energy drink to enhance physical and match performance in elite badminton players. Sixteen male and elite badminton players (25.4 ± 7.3 year; 71.8 ± 7.9 kg) participated in a double-blind, placebo-controlled and randomised experiment. On two different sessions, badminton players ingested 3 mg of caffeine per kg of body mass in the form of an energy drink or the same drink without caffeine (placebo). After 60 min, participants performed the following tests: handgrip maximal force production, smash jump without and with shuttlecock, squat jump, countermovement jump and the agility T-test. Later, a 45-min simulated badminton match was played. Players' number of impacts and heart rate was measured during the match. The ingestion of the caffeinated energy drink increased squat jump height (34.5 ± 4.7 vs. 36.4 ± 4.3 cm; P < 0.05), squat jump peak power (P < 0.05), countermovement jump height (37.7 ± 4.5 vs. 39.5 ± 5.1 cm; P < 0.05) and countermovement jump peak power (P < 0.05). In addition, an increased number of total impacts was found during the badminton match (7395 ± 1594 vs. 7707 ± 2033 impacts; P < 0.05). In conclusion, the results show that the use of caffeine-containing energy drink may be an effective nutritional aid to increase jump performance and activity patterns during game in elite badminton players.

The aim was to analyze the influence of competitive round on muscle strength, body-fluid balance, and renal function in elite badminton players during a real competition. Body mass, jump height during a countermovement jump, handgrip force, and urine samples were obtained from 13 elite badminton players (6 men and 7 women) before and after the 2nd-round and quarterfinal matches of the national Spanish badminton championship. Sweat rate was determined by using prematch-to-postmatch body-mass change and by weighing individually labeled fluid bottles. Sweat rates were 1.04 ± 0.62 and 0.98 ± 0.43 L/h, while rehydration rate was 0.69 ± 0.26 and 0.91 ± 0.52 L/h for the 2nd round and quarterfinals, respectively. Thus, dehydration was 0.47% ± 1.03% after the 2nd round and 0.23% ± 0.43% after the quarterfinals. There were no differences in prematch-to-postmatch jump height, but jump height was reduced from 37.51 ± 8.83 cm after the 2nd-round game to 34.82 ± 7.37 cm after the quarterfinals (P < .05). No significant differences were found in handgrip force when comparing prepost matches or rounds, although there were significant differences between dominant and nondominant hands (P < .05). The succession of rounds caused the appearance of proteinuria, hematuria, glycosuria, and higher nitrite and ketone concentrations in urine. Rehydration patterns during a real badminton competition were effective to prevent dehydration. A badminton match did not affect jump height or handgrip force, but jump height was progressively reduced by the competitive round. Badminton players' renal responses reflected diminished renal flux due to the high-intensity nature of this racket sport.

This study aimed at investigating the effects of a commercially available energy drink on shooting precision, jump performance and endurance capacity in young basketball players. Sixteen young basketball players (first division of a junior national league; 14.9 ± 0.8 years; 73.4 ± 12.4 kg; 182.3 ± 6.5 cm) volunteered to participate in the research. They ingested either (a) an energy drink that contained 3 mg of caffeine per kg of body weight or (b) a placebo energy drink with the same appearance and taste. After 60 min for caffeine absorption, they performed free throw shooting and three-point shooting tests. After that, participants performed a maximal countermovement jump (CMJ), a repeated maximal jumps test for 15 s (RJ-15), and the Yo-Yo intermittent recovery test level 1 (Yo-Yo IR1). Urine samples were obtained before and 30 min after testing. In comparison to the placebo, the ingestion of the caffeinated energy drink did not affect precision during the free throws (Caffeine = 70.7 ± 11.8 % vs placebo = 70.3 ± 11.0 %; P = 0.45), the three-point shooting test (39.9 ± 11.8 vs 38.1 ± 12.8 %; P = 0.33) or the distance covered in the Yo-Yo IR1 (2,000 ± 706 vs 1,925 ± 702 m; P = 0.19). However, the energy drink significantly increased jump height during the CMJ (38.3 ± 4.4 vs 37.5 ± 4.4 cm; P < 0.05) mean jump height during the RJ-15 (30.2 ± 3.6 vs 28.8 ± 3.4 cm; P < 0.05) and the excretion of urinary caffeine (1.2 ± 0.7 vs 0.1 ± 0.1 μg/mL; P < 0.05). The intake of a caffeine-containing energy drink (3 mg/kg body weight) increased jump performance although it did not affect basketball shooting precision.

Completing a marathon (42.2 km) is one of the more challenging sports activities. Besides the distance, the ambient conditions of the race (altitude, temperature, etc) can increase the physiological demands of the event. The purpose of this study was to investigate the relation between the altitude of the city in which the marathon is held and the marathon race time. For this purpose, we sought the race times of 16 popular marathons performed at different altitudes above sea level (range from ≈0 to 2800 meters above sea level). In these competitions, we analyzed the race times of the female and male runners who finished from 21(st) to 100(th) position. We excluded the top 20 male and female finishers from the analysis because elite athletes usually compete in marathons held at low altitudes above sea level. Ambient temperature, the positive cumulative elevation gain, and the number of participants were used as control variables. Finishing time in the marathon was positively correlated with the altitude of the competition for both male (r=0.78; p<0.05) and female participants (r=0.73; p<0.05). On average, each increase of 1000 meters above sea level augmented marathon race time by 10.8±0.6% in men and 12.3±0.7% in women. Compared to race times in the Rotterdam marathon (held at 0 meters above sea level), the time taken to complete the marathon was significantly higher in competitions held at an altitude of over 700 meters. In conclusion, the time taken to complete a marathon strongly depends on the altitude of the city in which the marathon is held. Selecting marathon competitions close to 0 m above sea level is a good strategy to maximize marathon performance.

Several investigations have demonstrated that running performance gradually decreases with age by using runners >25 years grouped in 5-year age brackets. The aim of this study was to determine the relationship between race time in marathon and age in elite marathoners by including all ages and 1-year intervals. Running times of the top ten men and women at 1-year intervals (from 18 to 75 years) in the New York City marathon were analyzed for the 2010 and 2011 races. Gender differences in performance times were analyzed between 18 and 70 years of age. The relationship between running time and runner's age was U-shaped: the lowest race time was obtained at 27 years (149 ± 14 min) in men and at 29 years (169 ± 17 min) in women. Before this age (e.g., 27 years for men and 29 years for women), running time increased by 4.4 ± 4.0 % per year in men and 4.4 ± 4.3 % per year in women. From this age on, running time increased by 2.4 ± 8.1 % per year in men and 2.5 ± 9.9 % per year in women. The sex difference in running time remained stable at ~18.7 ± 3.1 % from 18 to 57 years of age. After this, sex difference progressively increased with advancing age. In summary, endurance runners obtained their best performance in the marathon at 27 years in men and 29 in women. Thus, elite marathon runners should program their long-term training to obtain maximal performance during their late 20s.

Purpose: This study aimed at investigating the effectiveness of compression stockings to prevent muscular damage and preserve muscular performance during a half-ironman triathlon., Methods: Thirty-six experienced triathletes volunteered for this study. Participants were matched for age, anthropometric data and training status and placed into the experimental group (N = 19; using ankle-to-knee graduated compression stockings) or control group (N = 17; using regular socks). Participants competed in a half-ironman triathlon celebrated at 29 ± 3 °C and 73 ± 8% of relative humidity. Race time was measured by means of chip timing. Pre- and post-race, maximal height and leg muscle power were measured during a countermovement jump. At the same time, blood myoglobin and creatine kinase concentrations were determined and the triathletes were asked for perceived exertion and muscle soreness using validated scales., Results: Total race time was not different between groups (315 ± 45 for the control group and 310 ± 32 min for the experimental group; P = 0.46). After the race, jump height (-8.5 ± 3.0 versus -9.2 ± 5.3%; P = 0.47) and leg muscle power reductions (-13 ± 10 versus -15 ± 10 %; P = 0.72) were similar between groups. Post-race myoglobin (718 ± 119 versus 591 ± 100 μg/mL; P = 0.42) and creatine kinase concentrations (604 ± 137 versus 525 ± 69 U/L; P = 0.60) were not different between groups. Perceived muscle soreness (5.3 ± 2.1 versus 6.0 ± 2.0 arbitrary units; P = 0.42) and the rating of perceived effort (17 ± 2 versus 17 ± 2 arbitrary units; P = 0.58) were not different between groups after the race., Conclusion: Wearing compression stockings did not represent any advantage for maintaining muscle function or reducing blood markers of muscle damage during a triathlon event.

Background: Soccer is the most popular sport worldwide, with about 265 million players, both professionals and amateurs. Most research investigating soccer injuries has focused on professional players because they have greater exposure time, but most soccer players are at the recreational level., Purpose: To undertake a retrospective epidemiological study of the injuries sustained in Spanish amateur soccer during the 2010-2011 season., Study Design: Descriptive epidemiological study., Methods: Any injuries incurred by the 134,570 recreational soccer players (aged 18-55 years) registered with the Spanish Football Federation were reported to the federation's medical staff. A standardized medical questionnaire, based on the Fédération International de Football Association (FIFA) Medical and Research Centre (F-MARC) consensus for collection procedures in studies of soccer injuries, was used to classify the injury according to type, severity, location, and treatment., Results: A total of 15,243 injuries were reported, with an average of 0.11 injuries per player and per year. From the total number of injuries, 67.2% were classified as injuries that resulted in time loss, while the remaining 32.7% were injuries that required medical attention. Most injuries led to a minimum of 1 competitive match being missed (87%), and only 2.5% were recurrent injuries. The rate of injuries per 1000 hours of play was double during games (1.15/1000 hours) compared with during training (0.49/1000 hours). From the total number of injuries reported, 7.7% corresponded to goalkeepers, 24.2% to forwards, 33.8% to defenders, and 34.3% to midfielders. The knee (29.9%) and ankle joints (12.4%) were the most common body locations injured, while ligament sprains and ruptures accounted for 32.1% of the total injuries attended. Older amateur players (age ≥30 years) had a greater number of injuries per year and per 1000 hours of play than their younger counterparts., Conclusion: The risk of injury in amateur soccer is lower than that previously reported in professional players. The most common complaints in amateur players are knee ligament injuries. Further research is needed to investigate ways of reducing the incidence of injuries in amateur soccer.

The aim of this study was to determine the changes in body mass and myoglobinuria concentration in recreational runners during a marathon in a warm environment, and the relation of these changes to muscle fatigue. We recruited 138 amateur runners (114 men and 24 women) for the study. Before the race, leg muscle power output was measured during a countermovement jump on a force platform, body weight was measured, and a urine sample was obtained. Within 3 min of race completion (28 °C; 46% relative humidity), the runners repeated the countermovement jump, body weight was measured again, and a second urine sample was obtained. Myoglobin concentration was determined in the urine samples. After the race, mean body mass reduction was 2.2% ± 1.2%. Fifty-five runners (40% of the total) reduced their body mass by less than 2%, and 10 runners (7.2%) reduced their body mass by more than 4%. Only 3 runners increased their body mass after the marathon. Mean leg muscle power reduction was 16% ± 10%. Twenty-four runners reduced their muscle power by over 30%. No myoglobin was detected in the prerace urine specimens, whereas postrace urinary myoglobin concentration increased to 3.5 ± 9.5 μg·mL(-1) (p < 0.05). Muscle power change after the marathon significantly correlated with postrace urine myoglobin concentration (r = -0.55; p < 0.001), but not with body mass change (r = -0.08; p = 0.35). After a marathon in a warm environment, interindividual variability in body mass change was high, but only 7% of the runners reduced their body mass by more than 4%. The correlation between myoglobinuria and muscle power change suggests that muscle fatigue is associated with muscle breakdown.

Background: Completing a marathon is one of the most challenging sports activities, yet the source of running fatigue during this event is not completely understood. The aim of this investigation was to determine the cause(s) of running fatigue during a marathon in warm weather., Methodology/principal Findings: We recruited 40 amateur runners (34 men and 6 women) for the study. Before the race, body core temperature, body mass, leg muscle power output during a countermovement jump, and blood samples were obtained. During the marathon (27 °C; 27% relative humidity) running fatigue was measured as the pace reduction from the first 5-km to the end of the race. Within 3 min after the marathon, the same pre-exercise variables were obtained., Results: Marathoners reduced their running pace from 3.5 ± 0.4 m/s after 5-km to 2.9 ± 0.6 m/s at the end of the race (P<0.05), although the running fatigue experienced by the marathoners was uneven. Marathoners with greater running fatigue (> 15% pace reduction) had elevated post-race myoglobin (1318 ± 1411 v 623 ± 391 µg L(-1); P<0.05), lactate dehydrogenase (687 ± 151 v 583 ± 117 U L(-1); P<0.05), and creatine kinase (564 ± 469 v 363 ± 158 U L(-1); P = 0.07) in comparison with marathoners that preserved their running pace reasonably well throughout the race. However, they did not differ in their body mass change (-3.1 ± 1.0 v -3.0 ± 1.0%; P = 0.60) or post-race body temperature (38.7 ± 0.7 v 38.9 ± 0.9 °C; P = 0.35)., Conclusions/significance: Running pace decline during a marathon was positively related with muscle breakdown blood markers. To elucidate if muscle damage during a marathon is related to mechanistic or metabolic factors requires further investigation.

Background: Energy drinks have become the most used caffeine-containing beverages in the sport setting. The aim of this study was to determine the effects of two doses of a caffeine-containing energy drink on muscle performance during upper- and lower-body power-load tests., Methods: In a randomized order, twelve active participants ingested 1 and 3 mg of caffeine per kg of body weight using a commercially available energy drink (Fure®, ProEnergetics) or the same drink without caffeine (placebo; 0 mg/kg). After sixty minutes, resting metabolic rate, heart rate and blood pressure were determined. Then, half-squat and bench-press power production with loads from 10 to 100% of 1 repetition maximum was determined using a rotator encoder., Results: In comparison to the placebo, the ingestion of the caffeinated drink increased mean arterial pressure (82 ± 7 < 88 ± 8 ≈ 90 ± 6 mmHg for 0 mg/kg, 1 mg/kg, 3 mg/kg of caffeine, respectively; P < 0.05) and heart rate (57 ± 7 < 59 ± 8 < 62 ± 8 beats/min, respectively; P < 0.05) at rest in a dose response manner, though it did not affect resting metabolic rate. While the ingestion of 1 mg/kg of caffeine did not affect maximal power during the power-load tests with respect to the placebo, 3 mg/kg increased maximal power in the half-squat (2554 ± 167 ≈ 2549 ± 161 < 2726 ± 167 W, respectively; P < 0.05) and bench-press actions (349 ± 34 ≈ 358 ± 35 < 375 ± 33 W, respectively; P < 0.05)., Conclusions: A caffeine dose of at least 3 mg/kg in the form of an energy drink is necessary to significantly improve half-squat and bench-press maximal muscle power.

Background: The negative effects of dehydration on aerobic activities are well established. However, it is unknown how dehydration affects intermittent sports performance. The purpose of this study was to identify the level of dehydration in elite badminton players and its relation to muscle strength and power production., Methodology: Seventy matches from the National Spanish badminton championship were analyzed (46 men's singles and 24 women's singles). Before and after each match, jump height and power production were determined during a countermovement jump on a force platform. Participants' body weight and a urine sample were also obtained before and after each match. The amount of liquid that the players drank during the match was also calculated by weighing their individual drinking bottles., Results and Discussion: Sweat rate during the game was 1.14 ± 0.46 l/h in men and 1.02 ± 0.64 l/h in women. The players rehydrated at a rate of 1.10 ± 0.55 l/h and 1.01 ± 0.44 l/h in the male and female groups respectively. Thus, the dehydration attained during the game was only 0.37 ± 0.50% in men and 0.32 ± 0.83% in women. No differences were found in any of the parameters analyzed during the vertical jump (men: from 31.82 ± 5.29 to 32.90 ± 4.49 W/kg; p>0.05, women: from 26.36 ± 4.73 to 27.25 ± 4.44 W/kg; p>0.05). Post-exercise urine samples revealed proteinuria (60.9% of cases in men and 66.7% in women), leukocyturia (men = 43.5% and women = 50.0%) and erythrocyturia (men = 50.0% and women = 21.7%)., Conclusions: Despite a moderate sweat rate, badminton players adequately hydrated during a game and thus the dehydration attained was low. The badminton match did not cause muscle fatigue but it significantly increased the prevalence of proteinuria, leukocyturia and erythrocyturia.

Background: To investigate the cause/s of muscle fatigue experienced during a half-iron distance triathlon., Methodology/principal Findings: We recruited 25 trained triathletes (36±7 yr; 75.1±9.8 kg) for the study. Before and just after the race, jump height and leg muscle power output were measured during a countermovement jump on a force platform to determine leg muscle fatigue. Body weight, handgrip maximal force and blood and urine samples were also obtained before and after the race. Blood myoglobin and creatine kinase concentrations were determined as markers of muscle damage., Results: Jump height (from 30.3±5.0 to 23.4±6.4 cm; P<0.05) and leg power output (from 25.6±2.9 to 20.7±4.6 W · kg(-1); P<0.05) were significantly reduced after the race. However, handgrip maximal force was unaffected by the race (430±59 to 430±62 N). Mean dehydration after the race was 2.3±1.2% with high inter-individual variability in the responses. Blood myoglobin and creatine kinase concentration increased to 516±248 µg · L(-1) and 442±204 U · L(-1), respectively (P<0.05) after the race. Pre- to post-race jump change did not correlate with dehydration (r = 0.16; P>0.05) but significantly correlated with myoglobin concentration (r = 0.65; P<0.001) and creatine kinase concentration (r = 0.54; P<0.001)., Conclusions/significance: During a half-iron distance triathlon, the capacity of leg muscles to produce force was notably diminished while arm muscle force output remained unaffected. Leg muscle fatigue was correlated with blood markers of muscle damage suggesting that muscle breakdown is one of the most relevant sources of muscle fatigue during a triathlon.